CanSino Biologics Inc (CJH) - Total Liabilities

Latest as of December 2025: €2.22 Billion EUR ≈ $2.60 Billion USD

Based on the latest financial reports, CanSino Biologics Inc (CJH) has total liabilities worth €2.22 Billion EUR (≈ $2.60 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of CanSino Biologics Inc to evaluate the company's liquid asset resilience ratio.

CanSino Biologics Inc - Total Liabilities Trend (2016–2025)

This chart illustrates how CanSino Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of CanSino Biologics Inc.

CanSino Biologics Inc Competitors by Total Liabilities

The table below lists competitors of CanSino Biologics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Eightco Holdings Inc. NASDAQ:ORBS	USA	$13.42 Million
Oriental Kopi Holdings Berhad KLSE:0338	Malaysia	RM167.56 Million
Good Finance Securities Co Ltd TWO:6021	Taiwan	NT$28.31 Billion
Sinopec Shanghai Petrochemical Company Limited F:SGJH	Germany	€17.63 Billion
ARTRYA Ltd AU:AYA	Australia	AU$2.84 Million
Strata Critical Medical, Inc. NASDAQ:SRTA	USA	$41.89 Million
Select Harvests Ltd AU:SHV	Australia	AU$414.55 Million
Consolidated Water Co. Ltd F:CW2	Germany	€30.89 Million

Liability Composition Analysis (2016–2025)

This chart breaks down CanSino Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CJH net asset quality score to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.55	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.45	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.31	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how CanSino Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for CanSino Biologics Inc (2016–2025)

The table below shows the annual total liabilities of CanSino Biologics Inc from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€2.22 Billion ≈ $2.60 Billion	-27.04%
2024-12-31	€3.05 Billion ≈ $3.56 Billion	-24.39%
2023-12-31	€4.03 Billion ≈ $4.71 Billion	-4.55%
2022-12-31	€4.22 Billion ≈ $4.94 Billion	+26.97%
2021-12-31	€3.33 Billion ≈ $3.89 Billion	+391.17%
2020-12-31	€677.22 Million ≈ $791.74 Million	+115.69%
2019-12-31	€313.98 Million ≈ $367.08 Million	+6.96%
2018-12-31	€293.56 Million ≈ $343.20 Million	+13.33%
2017-12-31	€259.03 Million ≈ $302.84 Million	+131.90%
2016-12-31	€111.70 Million ≈ $130.59 Million	--

About CanSino Biologics Inc

F:CJH Germany Drug Manufacturers - Specialty & Generic

Market Cap

$446.71 Million

€382.09 Million EUR

Market Cap Rank

#12952 Global

#1369 in Germany

Share Price

€2.88

Change (1 day)

+1.41%

52-Week Range

€2.28 - €5.70

All Time High

€45.99